FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 126 filers reported holding FATE THERAPEUTICS INC in Q1 2019. The put-call ratio across all filers is 0.88 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $5,000 | -87.2% | 272 | -89.1% | 0.00% | – |
| Q3 2019 | $39,000 | -23.5% | 2,500 | 0.0% | 0.00% | – |
| Q2 2019 | $51,000 | +21.4% | 2,500 | +4.2% | 0.00% | – |
| Q1 2019 | $42,000 | +281.8% | 2,400 | +241.4% | 0.00% | – |
| Q3 2018 | $11,000 | +57.1% | 703 | 0.0% | 0.00% | – |
| Q2 2018 | $7,000 | 0.0% | 703 | 0.0% | 0.00% | – |
| Q1 2018 | $7,000 | – | 703 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $7,163,616 | 2.64% |
| Redmile Group, LLC | 13,124,427 | $27,823,785 | 1.32% |
| Monaco Asset Management SAM | 1,847,944 | $3,917,641 | 1.16% |
| Casdin Capital, LLC | 2,050,000 | $4,346,000 | 0.48% |
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $1,484,000 | 0.21% |
| GCM Grosvenor Holdings, LLC | 495,916 | $1,051,342 | 0.21% |
| Nebula Research & Development LLC | 163,617 | $346,868 | 0.18% |
| Bellevue Group AG | 4,851,579 | $10,285,347 | 0.17% |
| Bruce & Co., Inc. | 200,000 | $424,000 | 0.14% |
| XTX Topco Ltd | 192,920 | $408,990 | 0.07% |